Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria: Diagnosis of multiple myeloma (MM) Salmon-Durie stage IIA or IIIA OR progressive stage IA disease Meets at least 1 major AND 1 minor criterion OR at least 3 minor criteria The following are considered major criteria: Plasmacytoma on tissue biopsy Bone marrow plasmacytosis with >= 30% plasma cells Monoclonal globulin spike on serum protein electrophoresis exceeding 3.5 g/dL for immunoglobulin (Ig) G peaks or 2.0 g/dL for IgA peaks OR the presence of Bence-Jones protein of >= 1 g/24 hour-urine collection The following are considered minor criteria: Bone marrow plasmacytosis 10-29% Monoclonal globulin spike present, but less than the levels defined for a major criterion Lytic bone lesion Decrease in normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL No non-secretory MM (absent serum or urinary M-protein) Failed at least 1 prior systemic therapy* (e.g., chemotherapy, high-dose corticosteroids, thalidomide, or bortezomib) for the treatment of MM No solitary plasmacytoma Performance status - ECOG 0-2 More than 6 months Absolute neutrophil count > 1,200/mm^3 Platelet count > 75,000/mm^3 AST and ALT =< 2.5 times upper limit of normal (ULN) Bilirubin =< 1.5 times ULN Creatinine =< 1.5 times ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Fasting cholesterol =< 350 mg/dL Triglycerides =< 400 mg/dL No other concurrent uncontrolled illness No active or ongoing infection requiring oral or IV antibiotics No prior allergic reaction to compounds of similar chemical or biological composition to CCI-779 No other prior or concurrent malignancy or myelodysplasia except for the following: Basal cell or squamous cell skin cancer Carcinoma in situ of the cervix Localized cancer treated with surgery only with no evidence of disease for > 5 years No psychiatric illness or social situation that would preclude study compliance More than 4 weeks since prior thalidomide and recovered Prior high-dose chemotherapy and stem cell transplantation allowed More than 4 weeks since prior chemotherapy and recovered More than 4 weeks since prior high-dose corticosteroids and recovered More than 4 weeks since prior bortezomib and recovered More than 4 weeks since other prior anti-myeloma systemic therapy and recovered No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent investigational agents No other concurrent anticancer therapy